{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Partial response"},{"measurements":[{"groupId":"OG000","value":"21"}],"title":"Stable disease"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"description":"Tumor response rate using RECIST. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.","groups":[{"description":"The investigational drug used in this study is axitinib, and is available as tablets.","id":"OG000","title":"Axitinib Administration"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants evaluable at time of analysis.","reportingStatus":"POSTED","timeFrame":"12 Months","title":"Tumor Response Rate","type":"SECONDARY","unitOfMeasure":"Participants"}